About PILA PHARMA

PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.

PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.

Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.

PilaPharma

Announcement

Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2020, Lund, Sweden.

Watch the presentation in English here

(17-Nov-2020)

The Malmö-based company Pila Pharma, which has a drug candidate for type 2 diabetes, will be listed on one of the Swedish stock exchanges in the second quarter of next year.

Read the article in Swedish here

(17-Nov-2020)

Pila Pharma has scheduled its arrival on the Swedish stock market for May next year with the goal of fetching SEK 50m for developing the firm’s diabetes tablet leading up to phase III.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in English here
Read the article in Danish here

(17-Nov-2020)

Pila Pharma Press releases

PILA PHARMA announces plans for an IPO in Q2-2021

Read the Press release here

(17-Nov-2020)

Our Opinion and Concept Paper on the role of TRPV1 in diabetes published in Trends in Molecular Medicine.

Read the paper here

PILA PHARMA AB has been selected to be 1 of 200 SMEs to receive an SME Instrument Phase 1 grant (EUR 50 000).

Read the general EU announcement here and the project abstract here

Novo-forsker gjorde ph.d.-projekt til biotekselskab og forbereder nu fase 2-studie.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in Danish here

Om jag har rätt kan detta bli gigantisk.
An interview with CEO Dorte X. Gram by BioStock, Sweden.

Read the article in Swedish here

PILA PHARMA är klar med uppstartsfasen och flyttar ut från inkubatorn.
An interview with CEO Dorte X. Gram published by Medeon, Sweden.

Read the article in Swedish here

Pila Pharma

Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.

Check out the resulting article here

Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here

We are proud to be on the cover of the June 2017 issue of Affärslivet Norden, Medicine and Science magazine that focuses on innovation.
The magazine was distributed with Svenska Dagbladet.

Read the article in Swedish here
Read the magazine in Swedish here

Stora förhoppningar på nytt effektivt läkemedel mot diabetes typ 2.
An interview with CEO Dorte X. Gram published in ‘Analys Öresund’, Distributed with Dagens Industri, Sweden.

Read the article in Swedish here
Read the magazine in Swedish here

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA PHARMA was interviewed by Sydsvenskan, Sweden.

Read the article in Swedish here

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.